The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Evaluation of Combination Chemotherapy
Abstract
Isobologram and combination index (CI) analyses are the two most popular methods for evaluating drug interactions in combination cancer chemotherapy. As the commonly used CI-based software program uses linear regression, our first objective was to evaluate the effects of logarithmic data transformation on data analysis and conclusions. Monte-Carlo simulations were conducted with experimentally relevant parameter values to generate error-containing effect or concentration-effect data of single agents and combinations. The simulated data were then analyzed with linear and nonlinear regression. The results showed that data transformation reduced the accuracy and precision of the regression-derived IC50, curve shape parameter and CI values. Furthermore, as neither isobologram nor CI analyses provide output of concentration-effect curves for investigator evaluation, our second objective was to develop a method and the associated computer program/algorithm to (a) normalize drug concentrations in IC50 equivalents and thereby enable simultaneous presentation of the curves for single agents and combinations in a single plot for visual inspection of potential curve shifts, (b) analyze concentration-effect data with nonlinear regression, and (c) use the curve shift analysis simultaneously with isobologram and CI analyses. The applicability of this method was shown with experimentally obtained data for single agent doxorubicin and suramin and their combinations in cultured tumor cells. In summary, this method, by incorporating nonlinear regression and curve shift analysis, although retaining the attractive features of isobologram and CI analyses, reduced the potential errors introduced by logarithmic data transformation, enabled visual inspection of data variability and goodness of fit of regression analysis, and simultaneously provided information on the extent of drug interaction at different combination ratios/concentrations and at different effect levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves
Hill, A. V., Hill, A. L., & Hill, A. V. (1910) · The Journal of Physiology · Cited by 2,181
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine
Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., & Ham, J. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979253358 · Cited by 1,134
Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
Gordon Steel, G., & Peckham, M. J. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90044-0 · Cited by 908
A Method for Testing for Synergy with Any Number of Agents
Berenbaum, M. C. (1978) · Journal of Infectious Diseases · doi:10.1093/infdis/137.2.122 · Cited by 720
Greco, W. R., Park, H. S., & Rustum, Y. M. (1990) · PubMed · Cited by 219
Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs
Song, S., Wientjes, M. G., Gan, Y., & Au, J. L.-S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140210697 · Cited by 195
Self-citationLecture on the Antagonism between the Actions of Active Substances
Fraser, T. R. (1872) · BMJ · doi:10.1136/bmj.2.618.485 · Cited by 79
Cited by
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Duarte, D., & Vale, N. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100110 · Cited by 340
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Zhang, W., Konopleva, M., Shi, Y.-X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintás-Cardama, A., Small, D., Cortes, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm328 · Cited by 338
Combinational strategy for high-performance cancer chemotherapy
Qin, S.-Y., Cheng, Y.-J., Lei, Q., Zhang, A.-Q., & Zhang, X.-Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 301
Metadata
- Authors
- Zhao, L., Wientjes, M. G., & Au, J. L.-S.
- Venue
- Clinical Cancer Research
- Published
- 2004-12-01
- Volume
- 10
- Issue
- 23
- Pages
- 7994-8004
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2087408588
- Cited by
- 379
- References
- 13
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Combination Chemotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1087
- The paper
- Zhao, L., Wientjes, M. G., & Au, J. L.-S. (2004). Evaluation of Combination Chemotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.